Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Chemours Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Chemours Co's regulatory disclosures and financial reporting.
Chemours senior vice president Kristine M. Wellman reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 25,708 restricted stock units, which are scheduled to vest in three equal annual installments beginning on March 1, 2027. To cover tax obligations from previously vesting RSUs and dividend equivalent units, 3,359 shares were automatically withheld at a price of $18.24 per share, and the disclosure states that no shares were sold in the market. After these changes, she reports direct ownership of 73,750.6057 shares, RSUs, and dividend equivalent units in total.
Chemours executive Gerardo Familiar Calderon reported equity compensation changes involving company common stock. He received a grant of 25,708 shares of common stock at a price of $0.0000 per share as a grant, award, or other acquisition, structured as restricted stock units and related dividend equivalent units.
Separately, 2,635 shares were automatically withheld at $18.24 per share to satisfy tax obligations upon vesting of existing restricted stock units; footnotes state that no shares were sold and the transaction is exempt under Rule 16b-3. The new RSU award is scheduled to vest in three equal annual installments beginning on March 1, 2027, and the reported holdings include directly owned shares, RSUs, and dividend equivalent units.
Chemours Chief Executive Officer Denise Dignam reported equity compensation changes. She received a grant of 169,538 shares of common stock at $0.00 per share, in the form of restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations on vesting RSUs and related dividend equivalent units, 22,220 shares were automatically withheld at $18.24 per share; the company notes no shares were sold in the market. Following these transactions, she directly holds 335,313.8721 shares, including RSUs and dividend equivalent units.
Chemours Co reported that officer Michael Robert Foley acquired two grants of common stock in the form of restricted stock units. One award covers 25,013 RSUs that vest in three equal annual installments beginning on March 1, 2027, and another covers 50,027 RSUs scheduled to vest on March 1, 2029. Following these awards, Foley directly holds or is credited with 78,540 Chemours equity units, including directly owned shares, RSUs and related dividend equivalent units.
Chemours officer Joseph T. Martinko reported two stock transactions involving company common shares. On March 2, 2026, he acquired 28,488 shares at $0.00 per share through a grant classified as a grant, award, or other acquisition. On March 1, 2026, 2,789 shares at $18.24 per share were automatically withheld to cover tax obligations tied to vesting restricted stock units and related dividend equivalent units, and the footnote clarifies that no shares were sold on the market. After these transactions, his directly held and unit-based interests total 53,889.1669 shares, including common stock, restricted stock units, and dividend equivalent units. The RSU grant is scheduled to vest in three equal annual installments beginning on March 1, 2027, providing a staged equity-based compensation stream over time.
Chemours Chief Financial Officer Shane Hostetter reported equity compensation and related tax withholding transactions in company common stock. On March 2, he acquired 47,387 shares through a grant or award at a stated price of $0.0000 per share, increasing his directly owned and unit-based holdings to 101,857.1999 shares. A related footnote states this restricted stock unit (RSU) award is scheduled to vest in three equal annual installments beginning on March 1, 2027. On March 1, 3,232 shares at $18.2400 per share were automatically withheld to satisfy tax obligations on vesting RSUs and dividend equivalent units, with the filing clarifying that no shares were sold. Following the tax-withholding disposition, his directly held total was 54,470.1999 shares, which a footnote explains includes directly owned shares, RSUs and dividend equivalent units.
Chemours Co Chief Accounting Officer David Will reported an equity award and a related tax withholding transaction. He received a grant covering 8,337 shares of common stock at no cost, structured as an RSU award scheduled to vest in three equal annual installments beginning on March 1, 2027. In a separate transaction, 699 shares were automatically withheld at $18.24 per share to satisfy tax obligations on vesting restricted stock units and dividend equivalent units; the footnote states that no shares were sold in the market. Following these transactions, his directly owned holdings, including RSUs and dividend equivalent units, total 33,083.5415 shares.
Chemours Co senior vice president and general counsel Kristine M. Wellman reported routine equity compensation transactions in company common stock. She acquired 1,781 shares at no cost through performance stock units granted under the Long Term Incentive Plan, which vested after the compensation committee certified performance conditions were met.
To cover related tax obligations on vesting restricted stock units and dividend equivalent units, 675 shares were automatically withheld at a price of $18.41 per share; the footnotes state no shares were sold on the market. After these transactions and an adjustment correcting a prior administrative error, her directly owned, restricted stock unit, and dividend equivalent unit holdings total 51,401.6057 shares.
Chemours Co Chief Executive Officer Denise Dignam received 2,261 shares of common stock as a performance-based stock award tied to 2023 compensation, issued at no cash cost to her after performance conditions were certified. To cover taxes on vesting, 742 shares were automatically withheld at $18.4100 per share, and the footnotes state that no shares were sold. Following these transactions and an adjustment for a prior administrative error, her directly owned and related holdings total 187,995.8721 shares, including restricted stock units and dividend equivalent units.
The Chemours Company filed a Form 8-K to report a private debt financing. The company launched and priced an upsized offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034, increased from a previously announced $600,000,000 offering size.
The notes mature on March 15, 2034 and will pay interest semi-annually on March 15 and September 15, starting September 15, 2026. Chemours intends to use the net proceeds to redeem its outstanding 5.375% senior notes due 2027 and partially redeem its outstanding 5.750% senior notes due 2028. The notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S.